Company profile
Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology: Pharmaceutical Preparations
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06874010 | phase1_2 | recruiting | 2025-06-01 | 2026-12-01 | Design Therapeutics, Inc. | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia |
| NCT06772870 | phase1 | not_yet_recruiting | 2025-02-01 | 2025-09-01 | Design Therapeutics, Inc. | A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants |
| NCT07024693 | phase2 | recruiting | 2025-07-30 | 2026-09-01 | Design Therapeutics, Inc. | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy |
| NCT05285540 | phase1 | completed | 2022-03-11 | 2022-12-19 | Design Therapeutics, Inc. | Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia |
| NCT05573698 | phase1 | completed | 2022-09-27 | 2023-08-25 | Design Therapeutics, Inc. | Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia |
FDA applications (0)
No records yet.